AUM and trading activity drives Oppenheimer's wealth management business. Read why we remain bullish on OPY stock.

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

Over the years, we’ve heard hundreds of time about how we have enough nuclear weapons to destroy the world. But is that ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

After the music industry gave out its prestigious Grammys Sunday, the film community is gearing up for its ceremony to take ...

Patient Capital Management stated the following regarding Coinbase Global, Inc. (NASDAQ:COIN) in its Q4 2024 investor letter: ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target ...

Hulu has renewed the hit series Tell Me Lies for a third season, sharing on social media: “couldn’t keep you waiting any ...

Last year’s Oscar winners Emma Stone, Cillian Murphy, Da’Vine Joy Randolph and Robert Downey Jr. are set to return to the ...

Real’s first book, “I Don’t Want to Talk About It: Overcoming the Secret Legacy of Male Depression,” is an extended ...

Oppenheimer (NYSE:OPY – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Oppenheimer Trading ...